Stockscreener 앱 받기
46.10
1.66%
-0.78
시간 외 거래:
46.10
전일 마감가:
$46.88
열려 있는:
$46.14
하루 거래량:
1.05M
Relative Volume:
0.52
시가총액:
$7.73B
수익:
$1.56B
순이익/손실:
$152.72M
주가수익비율:
51.26
EPS:
0.8994
순현금흐름:
$221.80M
1주 성능:
-2.76%
1개월 성능:
-7.19%
6개월 성능:
+57.45%
1년 성능:
+59.41%
1일 변동 폭
$45.80
$46.93
1주일 범위
$45.80
$48.73
52주 변동 폭
$25.16
$55.67
Alkermes Plc Stock (ALKS) Company Profile
명칭
Alkermes Plc
전화
00-353-1-772-8000
주소
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
46.10 | 8.06B | 1.56B | 152.72M | 221.80M | 0.8994 |
TAK
Takeda Pharmaceutical Co Adr
|
18.45 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.36 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.60 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.81 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
487.61 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-06-29 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2025-11-11 | 개시 | Truist | Buy |
| 2025-09-26 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | 개시 | Wells Fargo | Overweight |
| 2025-07-15 | 개시 | Goldman | Buy |
| 2025-06-17 | 업그레이드 | UBS | Neutral → Buy |
| 2025-05-28 | 개시 | Needham | Buy |
| 2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | 업그레이드 | UBS | Sell → Neutral |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-11-05 | 업그레이드 | Stifel | Hold → Buy |
| 2024-06-17 | 개시 | TD Cowen | Buy |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-20 | 다운그레이드 | UBS | Neutral → Sell |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-10-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-10-17 | 개시 | UBS | Neutral |
| 2022-11-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-08-16 | 개시 | Piper Sandler | Neutral |
| 2022-04-22 | 재개 | Goldman | Buy |
| 2022-04-20 | 개시 | Goldman | Buy |
| 2022-01-27 | 업그레이드 | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | 개시 | Citigroup | Neutral |
| 2021-10-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-09-02 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-10-15 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-02-14 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | 재확인 | H.C. Wainwright | Neutral |
| 2020-02-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-01-31 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-05-31 | 개시 | H.C. Wainwright | Neutral |
| 2019-05-01 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-12-19 | 다운그레이드 | Goldman | Neutral → Sell |
| 2018-12-14 | 개시 | Wolfe Research | Underperform |
| 2018-12-13 | 다운그레이드 | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | 개시 | Piper Jaffray | Neutral |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-06-21 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | 개시 | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
모두보기
Alkermes Plc 주식(ALKS)의 최신 뉴스
Alkermes PLC (ALKS) Shares Fall 4.4% -- What GF Score of 64 Tells Investors - GuruFocus
Alkermes ends Amneal VIVITROL supply pact without penalties - scanx.trade
Alkermes reports phase 2 Vibrance-2 data; alixorexton meets dual primary endpoints in narcolepsy type 2 - scanx.trade
Alkermes (ALKS) Shares: Posts a 3.31% Loss to $48.52 for the Current Session; Current Setup: Traders Can Monitor the $46.09-$50.95 Range for the Current SessionStatistical Arbitrage - vinanet.vn
Q2 2026 Alkermes Plc Earnings Call Transcript - GuruFocus
Empowered Funds LLC Sells 53,381 Shares of Alkermes plc $ALKS - MarketBeat
STU:8AK EV-to-OCF: 37.38 — 44% Above Median - GuruFocus
Alkermes (ALKS) SVP, Chief Commercial Officer Christian Nichols Sells 7,576 Shares - GuruFocus
Alkermes (NASDAQ:ALKS) SVP Sells $372,966.48 in Stock - MarketBeat
Alkermes (NASDAQ: ALKS) holder to sell 7,576 shares worth $373K - Stock Titan
Alkermes (ALKS) Advances 1.53% as Shares Hold Firm Above Key SupportVOLD Alert - Vinanet
Alkermes Plc (ALKS) Stock Analysis: A Look At The 14.15% Potential Upside - DirectorsTalk Interviews
Alkermes (ALKS) Eases to $49.06: Key Levels to Watch After 0.79% DipPrice Target - Vinanet
S&CO Inc. Takes Position in Alkermes plc $ALKS - MarketBeat
Alkermes PLC (ALKS) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes - Stocktwits
Alkermes plc $ALKS Stock Position Trimmed by Empowered Funds LLC - MarketBeat
Quantinno Capital Management LP Grows Holdings in Alkermes plc $ALKS - MarketBeat
Bank of America Corp DE Trims Position in Alkermes plc $ALKS - MarketBeat
ALKS Stock Rises 27% in 3 Months: Here's What You Should Know - TradingView
Alkermes Lowers Interest Rate Spreads with Amendment to Credit Agreement - Kalkine Media
Alkermes amends credit agreement to reduce interest rates on term loans - Investing.com Nigeria
Form 8K Alkermes plc. For: 12 August By Investing.com - Investing.com Canada
Alkermes Reduces Spreads on $1.52 Billion Term Loans by Up to 75 bps - TradingView
Alkermes (NASDAQ: ALKS) lowers interest spreads on large term loan A and B debt - Stock Titan
Alkermes plc Enters into Amendment to Credit Agreement Reducing Interest Rate Spread on Term Loan Facilities - marketscreener.com
Hennion & Walsh Asset Management Inc. Makes New Investment in Alkermes plc $ALKS - MarketBeat
Could Alkermes plc (ALKS) Stock Rebound After Investors Look Beyond Near-Term Profit Pressure? - Yahoo Finance
Alkermes plc (ALKS) Stock Analysis: Evaluating a 13.89% Upside in the Biopharmaceutical Sector - DirectorsTalk Interviews
Alkermes Plc (ALKS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Did Alkermes’ (ALKS) Profit Slide and Cash-Conserving Moves Just Shift Its Investment Narrative? - simplywall.st
The Manufacturers Life Insurance Company Sells 42,319 Shares of Alkermes plc $ALKS - MarketBeat
Royal Bank of Canada Sells 21,159 Shares of Alkermes plc $ALKS - MarketBeat
(ALKS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Amundi Increases Stake in Alkermes plc $ALKS - MarketBeat
Alkermes plc $ALKS Shares Acquired by California State Teachers Retirement System - MarketBeat
Sei Investments Co. Has $5.44 Million Stake in Alkermes plc $ALKS - MarketBeat
Major Decision: Nancy Snyderman Exercises Options, Realizing $116K At Alkermes - Benzinga
Alkermes Insider Sold Shares Worth $2,239,076, According to a Recent SEC Filing - marketscreener.com
Form 4 Alkermes plc. For: 3 August By Investing.com - Investing.com South Africa
Alkermes Plc (ALKS) Stock Analysis: A Compelling 14% Upside Potential For Investors - DirectorsTalk Interviews
Research Analysts Set Expectations for Alkermes Q3 Earnings - MarketBeat
Seven Fleet Capital Management LP Acquires New Shares in Alkermes plc $ALKS - MarketBeat
Why Alkermes (ALKS) Is Down 7.4% After Q2 Profit Drop And New Equity Shelf Filing - simplywall.st
Is Alkermes (ALKS) Priced For Orexin Success Or Too Rich? - Yahoo Finance
Alkermes plc 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ALKS) 2026-07-31 - Seeking Alpha
H.C. Wainwright reiterates Neutral stock rating on Alkermes - Investing.com
Stempoint Capital LP Acquires Shares of 80,492 Alkermes plc $ALKS - MarketBeat
Alkermes Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Alkermes' Core Business Backed Q2 Beat, Orexin Pipeline to Serve as Catalyst, RBC Says - marketscreener.com
Entropy Technologies LP Sells 40,839 Shares of Alkermes plc $ALKS - MarketBeat
Alkermes Plc (ALKS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.50%
0.33%
자본화:
|
볼륨(24시간):